By: PBR staff writer
Source: Pharmaceutical Business Review
Date of Publication: April 17th, 2020
LegoChem Biosciences, based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.